je.st
news
UPDATE 2-AbbVie oral hep C drugs cure 96 pct in late stage trial
2013-12-11 01:07:56| Biotech - Topix.net
AbbVie Inc's all-oral hepatitis C therapy cured 96 percent of difficult-to-treat patients in a late-stage clinical trial after 12 weeks, keeping the company well placed in a highly competitive race to deliver new treatments for the serious liver disease.
Tags: update
late
stage
trial
Category:Biotechnology and Pharmaceuticals
Latest from this category |
All news |
||||||||||||||||||||
|
|
||||||||||||||||||||